Download PDF
Laryngorhinootologie 2015; 94(02): 77-85
DOI: 10.1055/s-0034-1387699
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Aktueller Stand der chirurgischen und adjuvanten Therapie der Malignome der Gesichtshaut und der Ohrmuschel

Current Surgical and Adjuvant Therapy Concepts of Malignant Tumors of the Facial Skin and the Pinna
A. Kolk
1   Klinik und Poliklinik für Mund-Kiefer-Gesichtschirurgie, Klinikum rechts der Isar, Technische Universität München, München
,
K. Wermker
2   Mund-Kiefer-Gesichtschirurgie, plastische und ästhetische Operationen, Fachklinik Hornheide, Münster
,
H. Bier
3   Hals-, Nasen- und Ohrenklinik, Klinikum rechts der Isar, Technische Universität München, München
,
C. Götz   *
1   Klinik und Poliklinik für Mund-Kiefer-Gesichtschirurgie, Klinikum rechts der Isar, Technische Universität München, München
,
A. W. Eckert   *
4   Universitätsklinik und Poliklinik für Mund-Kiefer- und Plastische ­Gesichtschirurgie, Martin-Luther-Universität Halle-­Wittenberg, Halle
› Author Affiliations
Further Information

Publication History

Publication Date:
06 February 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Stellten die verschiedenen malignen Neoplasien (MN) der Haut [1] vor 2 Jahrzehnten noch eine relativ seltene Entität dar, sind sie heute mit zunehmender Inzidenz weltweit stark verbreitet. MN der Haut, des größten menschlichen Organes, können von allen Strukturen und Schichten ausgehen. Während früher Hautkrebs-Erkrankungen überwiegend nach dem 60. Lebensjahr auftraten, steigt die Inzidenz aktuell auch bei jüngeren Jahrgängen. U. a. starke Sonnenbrände in der Kindheit und vor dem 20. Lebensjahr stellen neben anderen Einflüssen wichtige Risikofaktoren für die Entstehung von MN der Haut dar. Eine erhöhte Exposition gegenüber UV-Strahlen findet sich vor allem bei der Gesichtshaut, wo Basalzellkarzinome, Plattenepithelkarzinome, maligne Melanome und Merkelzellkarzinome die häufigsten MN darstellen. Frühzeitige Diagnosestellung und eine adäquate (meist chirurgische) Behandlung auch unter funktionellen Gesichtspunkten unter Einbindung in eine interdisziplinäre Therapieentscheidung sind entscheidend für die Prognose sämtlicher MN. Unter Berücksichtigung der zunehmenden Inzidenz der o. g. MN werden die Grenzen der chirurgischen Therapiemöglichkeiten und multimodale Behandlungsaspekte bis hin zu neuen, teils noch in der Prüfphase befindlichen Optionen nach neuesten Erkenntnissen und Vorgaben dargestellt.

Abstract

Malignant tumors of the skin had been a rare entity 2 decades ago. Today they are spread rapidly worldwide. Malignant neoplasms of the skin, the largest human organ, may occur from all structures and layers. While previously skin cancer ­occurred mainly after the age of 60, the incidence increases now in younger ages. Strong sunburns in the childhood and before the age of 20 are important risk factors for the development of malignancies of the skin. An increased exposure to UV rays is found especially in the facial skin, where basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Merkel cell carcinomas are the most common malignancies. Early diagnosis of malignancies and therapy-oriented mostly surgical approaches are crucial for the prognosis of all skin cancers. Therefore under the aspect of the increasing incidence these topics will be pointed out according to the latest findings including current multimodal therapy concepts and future treatment options.

Schlüsselwörter

Basalzellkarzinom - Plattenepithelkarzinom - Melanom - Merkelzellkarzinom - multimodale Therapie

Key words

basal cell carcinoma - squamous cell carcinoma - melanoma - Merkel cell carcinoma - multimodal therapy
*

* C. Götz and A. W. Eckert haben zu gleichen Teilen zu diesem Manuskript beigetragen.


 

  • Literatur

  • 1 Barlow RJ, Ramnarain N, Smith N, Mayou B, Markey AC, Walker NP. Excision of selected skin tumours using Mohs’ micrographic surgery with horizontal paraffin-embedded sections. Br J Dermatol 1996; 135: 911-917
    CrossrefPubMedGoogle Scholar
  • 2 Abbas JS, Hashem SI, Faraj WG, Khalifeh MJ, Horani MH, Salti IS. The outcome of cervical exploration for asymptomatic and symptomatic patients with primary hyperparathyroidism. World J Surg 2006; 30: 69-75
    CrossrefPubMedGoogle Scholar
  • 3 Ariani N, Visser A, van Oort RP, Kusdhany L, Rahardjo TB, Krom BP, van der Mei HC, Vissink A. Current state of craniofacial prosthetic rehabilitation. Int J Prosthodont 2013; 26: 57-67
    CrossrefPubMedGoogle Scholar
  • 4 Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-719
    CrossrefPubMedGoogle Scholar
  • 5 Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999; 135: 781-786
    PubMedGoogle Scholar
  • 6 Karalis A, Tischkowitz M, Millington GW. Dermatological manifestations of inherited cancer syndromes in children. Br J Dermatol 2011; 164: 245-256
    CrossrefPubMedGoogle Scholar
  • 7 Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma – molecular biology and potential new therapies. J Clin Invest 2012; 122: 455-463
    CrossrefPubMedGoogle Scholar
  • 8 Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol 2014; 70: e88-e99
    CrossrefPubMedGoogle Scholar
  • 9 Mohan SV, Chang AL. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Dermatol Rep 2014; 3: 40-45
    PubMedGoogle Scholar
  • 10 Sekulic A et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179
    CrossrefPubMedGoogle Scholar
  • 11 Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 2004; 329: 705
    CrossrefPubMedGoogle Scholar
  • 12 Kolk A, Wolff KD, Smeets R, Kesting M, Hein R, Eckert AW. Melanotic and non-melanotic malignancies of the face and external ear – A review of current treatment concepts and future options. Cancer Treat Rev 2014; 40: 819-837
    CrossrefPubMedGoogle Scholar
  • 13 Morton CA. The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments?. J Dermatolog Treat 2002; 13 (Suppl. 01) S25-S29
    CrossrefPubMedGoogle Scholar
  • 14 Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, Calzavara-Pinton P, Varma S, Roelandts R, Wolf P. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-553
    PubMedGoogle Scholar
  • 15 van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, Willemze R, Marijnen CA. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010; 95: 245-249
    CrossrefPubMedGoogle Scholar
  • 16 Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, Neumann HA. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766-1772
    CrossrefPubMedGoogle Scholar
  • 17 Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2009; 17: 309-324
    CrossrefPubMedGoogle Scholar
  • 18 Hampton T. Skin cancer’s ranks rise: immunosuppression to blame. JAMA 2005; 294: 1476-1480
    CrossrefPubMedGoogle Scholar
  • 19 Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous Cell Carcinoma – Similarities and Differences among Anatomical Sites. Am J Cancer Res 2011; 1: 275-300
    PubMedGoogle Scholar
  • 20 Lomas A, Leonardi-Bee J, Bath-Hextall F. A Systematic Review of worldwide incidence of Non-melanoma skin cancer. Br J Dermatol 2012;
    PubMedGoogle Scholar
  • 21 Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005; 23: 759-765
    CrossrefPubMedGoogle Scholar
  • 22 Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer 2006; 106: 2389-2396
    CrossrefPubMedGoogle Scholar
  • 23 Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, Breuninger H. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720
    CrossrefPubMedGoogle Scholar
  • 24 O’Hara J, Ferlito A, Takes RP, Rinaldo A, Strojan P, Shaha AR, Rodrigo JP, Paleri V. Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland–a review of current recommendations. Head Neck 2011; 33: 1789-1795
    CrossrefPubMedGoogle Scholar
  • 25 Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26: 1-26
    CrossrefPubMedGoogle Scholar
  • 26 Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63: 8-18
    CrossrefPubMedGoogle Scholar
  • 27 Akgul B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006; 208: 165-175
    CrossrefPubMedGoogle Scholar
  • 28 Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289-297
    CrossrefPubMedGoogle Scholar
  • 29 Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol 2006; 142: 755-758
    PubMedGoogle Scholar
  • 30 Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138: 758-763
    CrossrefPubMedGoogle Scholar
  • 31 Forest VII, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer 2010; 116: 1298-1304
    CrossrefPubMedGoogle Scholar
  • 32 Breuninger H, Eigentler T, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Garbe C, Grabbe S. Brief S2k guidelines – Cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2013; 11 (Suppl. 03) 37-45 39-47
    PubMedGoogle Scholar
  • 33 Wermker K, Kluwig J, Schipmann S, Klein M, Schulze HJ, Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. Europ J Surg Oncol 2014; (in press)
    PubMedGoogle Scholar
  • 34 Clark RR, Soutar DS, Hunter KD. A retrospective analysis of histological prognostic factors for the development of lymph node metastases from auricular squamous cell carcinoma. Histopathology 2010; 57: 138-146
    CrossrefPubMedGoogle Scholar
  • 35 Ying YL, Johnson JT, Myers EN. Squamous cell carcinoma of the parotid gland. Head Neck 2006; 28: 626-632
    CrossrefPubMedGoogle Scholar
  • 36 Vauterin TJ, Veness MJ, Morgan GJ, Poulsen MG, O’Brien CJ. Patterns of lymph node spread of cutaneous squamous cell carcinoma of the head and neck. Head Neck 2006; 28: 785-791
    CrossrefPubMedGoogle Scholar
  • 37 Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983
    PubMedGoogle Scholar
  • 38 Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005; 115: 870-875
    CrossrefPubMedGoogle Scholar
  • 39 Dona E, Veness MJ, Cakir B, Morgan GJ. Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. ANZ J Surg 2003; 73: 692-696
    CrossrefPubMedGoogle Scholar
  • 40 Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007; 29: 621-631
    CrossrefPubMedGoogle Scholar
  • 41 Wolff K-D, Follmann M, Nast A. Clinical practice guideline: The diagnosis and treatment of oral cavity cancer. Dtsch Arztebl Int 2012; 109: 829-835
    PubMedGoogle Scholar
  • 42 Kolk A, Jubitz N, Mengele K, Mantwill K, Bissinger O, Schmitt M, Kremer M, Holm PS. Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. Br J Cancer 2011; 105: 1864-1873
    CrossrefPubMedGoogle Scholar
  • 43 Veness MJ, Morgan GJ, Sathiyaseelan Y, Gebski V. Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients?. ANZ J Surg 2005; 75: 101-105
    CrossrefPubMedGoogle Scholar
  • 44 Jarkowski A, Hare R, Loud P, Skitzki JJ, Kane 3rd JM, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A, Khushalani NI. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. Am J Clin Oncol 2014;
    PubMedGoogle Scholar
  • 45 Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev 2010; p. CD007869
    PubMedGoogle Scholar
  • 46 Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280-290
    CrossrefPubMedGoogle Scholar
  • 47 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403
    CrossrefPubMedGoogle Scholar
  • 48 Kalimullah FA, Brown CW. Compliance with follow-up among patients with melanoma and non-melanoma skin cancers. Dermatol Online J 2014; 20: 21537
    PubMedGoogle Scholar
  • 49 Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O’Neill T, Ruka W, Bliss JM. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766
    CrossrefPubMedGoogle Scholar
  • 50 Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 2013; 11 (Suppl. 06) 1-116 1–126
    PubMedGoogle Scholar
  • 51 Mitteldorf C, Bertsch HP, Jung K, Thoms KM, Schön MP, Tronnier M, Kretschmer L. Sentinel Node Biopsy Improves Prognostic Stratification in Patients with Thin (pT1) Melanomas and an Additional Risk Factor. Ann Surg Oncol 2014;
    PubMedGoogle Scholar
  • 52 Doting EH, de Vries M, Plukker JT, Jager PL, Post WJ, Suurmeijer AJ, Hoekstra HJ. Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome?. J Surg Oncol 2006; 93: 564-570
    CrossrefPubMedGoogle Scholar
  • 53 Villaret AB, Piazza C, Peretti G, Calabrese L, Ansarin M, Chiesa F, Pellini R, Spriano G, Nicolai P. Multicentric prospective study on the prevalence of sublevel IIb metastases in head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 897-903
    CrossrefPubMedGoogle Scholar
  • 54 Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB. MSLT Group . Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609
    CrossrefPubMedGoogle Scholar
  • 55 Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13: 589-597
    CrossrefPubMedGoogle Scholar
  • 56 Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051-1055
    CrossrefPubMedGoogle Scholar
  • 57 Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046
    CrossrefPubMedGoogle Scholar
  • 58 Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJ. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 2014; 34: 1493-1505
    PubMedGoogle Scholar
  • 59 Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010; 22: 178-183
    CrossrefPubMedGoogle Scholar
  • 60 Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714
    CrossrefPubMedGoogle Scholar
  • 61 Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris 3rd HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703
    CrossrefPubMedGoogle Scholar
  • 62 Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010; 37: 20-27
    CrossrefPubMedGoogle Scholar
  • 63 Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel Cell Carcinoma: Epidemiology, Target, and Therapy. Curr Dermatol Rep 2014; 3: 46-53
    PubMedGoogle Scholar
  • 64 Eng TY, Boersma MG, Fuller CD, Goytia V, Jones 3rd WE, Joyner M, Nguyen DD. A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 2007; 30: 624-636
    CrossrefPubMedGoogle Scholar
  • 65 Kachare SD, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. Sentinel lymph node biopsy is associated with improved survival in Merkel cell carcinoma. Ann Surg Oncol 2014; 21: 1624-1630
    CrossrefPubMedGoogle Scholar
  • 66 Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 2007; 25: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 67 Hasan S, Liu L, Triplet J, Li Z, Mansur D. The role of postoperative radiation and chemoradiation in merkel cell carcinoma: a systematic review of the literature. Front Oncol 2013; 3: 276
    PubMedGoogle Scholar